Arzoxifene

Drug Profile

Arzoxifene

Alternative Names: Arzoxifene hydrochloride; LY353381; SERM III; SERM-3

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Osteoporosis therapies; Piperidines; Thiophenes
  • Mechanism of Action Selective estrogen receptor agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer; Postmenopausal osteoporosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2009 Efficacy data from a phase III trial in postmenopausal osteoporosis presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
  • 25 Mar 2009 Efficacy and safety data from the phase III, NEXT trial in Postmenopausal osteoporosis released by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top